155 related articles for article (PubMed ID: 19787152)
21. Neonatal screening for cystic fibrosis: result of a pilot study using both immunoreactive trypsinogen and cystic fibrosis gene mutation analyses.
Férec C; Verlingue C; Parent P; Morin JF; Codet JP; Rault G; Dagorne M; Lemoigne A; Journel H; Roussey M
Hum Genet; 1995 Nov; 96(5):542-8. PubMed ID: 8530001
[TBL] [Abstract][Full Text] [Related]
22. PAP assays in newborn screening for cystic fibrosis: a population-based cost-effectiveness study.
Seror V; Cao C; Roussey M; Giorgi R
J Med Screen; 2016 Jun; 23(2):62-9. PubMed ID: 26304152
[TBL] [Abstract][Full Text] [Related]
23. Newborn screening for cystic fibrosis in Wisconsin: comparison of biochemical and molecular methods.
Gregg RG; Simantel A; Farrell PM; Koscik R; Kosorok MR; Laxova A; Laessig R; Hoffman G; Hassemer D; Mischler EH; Splaingard M
Pediatrics; 1997 Jun; 99(6):819-24. PubMed ID: 9164776
[TBL] [Abstract][Full Text] [Related]
24. Efficacy of statewide neonatal screening for cystic fibrosis by assay of trypsinogen concentrations.
Hammond KB; Abman SH; Sokol RJ; Accurso FJ
N Engl J Med; 1991 Sep; 325(11):769-74. PubMed ID: 1870650
[TBL] [Abstract][Full Text] [Related]
25. Positive neonatal screening for cystic fibrosis in neonates with renal failure.
Oosterveld MJ; Schilperoort JV; Lilien MR; Arets HG
Thorax; 2010 Jul; 65(7):652-3. PubMed ID: 20627926
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of the Quantase neonatal immunoreactive trypsinogen (IRT) screening assay for cystic fibrosis.
Ball CL; Montgomery MD; Bridge PJ; Lyon ME
Clin Chem Lab Med; 2005; 43(5):570-2. PubMed ID: 15899682
[No Abstract] [Full Text] [Related]
27. [Neonatal screening for cystic fibrosis].
Tellería Orriols JJ; Alonso Ramos MJ; Garrote Adrados JA; Fernández Carvajal I; Blanco Quirós A
An Esp Pediatr; 2002 Jul; 57(1):60-5. PubMed ID: 12139895
[TBL] [Abstract][Full Text] [Related]
28. Comparison between two newborn screening strategies for cystic fibrosis in Argentina: IRT/IRT versus IRT/PAP.
Teper A; Smithuis F; Rodríguez V; Salvaggio O; Maccallini G; Aranda C; Lubovich S; Zaragoza S; García-Bournissen F
Pediatr Pulmonol; 2021 Jan; 56(1):113-119. PubMed ID: 33095477
[TBL] [Abstract][Full Text] [Related]
29. Immunoreactive trypsinogen screening for cystic fibrosis: characterization of infants with a false-positive screening test.
Rock MJ; Mischler EH; Farrell PM; Bruns WT; Hassemer DJ; Laessig RH
Pediatr Pulmonol; 1989; 6(1):42-8. PubMed ID: 2704582
[TBL] [Abstract][Full Text] [Related]
30. Newborn screening for cystic fibrosis: do we need a second IRT?
Price JF
Arch Dis Child; 2006 Mar; 91(3):209-10. PubMed ID: 16492882
[TBL] [Abstract][Full Text] [Related]
31. Neonatal screening strategy for cystic fibrosis using immunoreactive trypsinogen and direct gene analysis.
Ranieri E; Ryall RG; Morris CP; Nelson PV; Carey WF; Pollard AC; Robertson EF
BMJ; 1991 May; 302(6787):1237-40. PubMed ID: 2043846
[TBL] [Abstract][Full Text] [Related]
32. Thirty-years of screening for cystic fibrosis in East Anglia.
Calvin J; Hogg SL; McShane D; McAuley SA; Iles R; Ross-Russell R; MacLean FM; Heeley ME; Heeley AF;
Arch Dis Child; 2012 Dec; 97(12):1043-7. PubMed ID: 23076339
[TBL] [Abstract][Full Text] [Related]
33. Newborn Screening for Cystic Fibrosis in California.
Kharrazi M; Yang J; Bishop T; Lessing S; Young S; Graham S; Pearl M; Chow H; Ho T; Currier R; Gaffney L; Feuchtbaum L;
Pediatrics; 2015 Dec; 136(6):1062-72. PubMed ID: 26574590
[TBL] [Abstract][Full Text] [Related]
34. A survey of newborn screening for cystic fibrosis in Europe.
Southern KW; Munck A; Pollitt R; Travert G; Zanolla L; Dankert-Roelse J; Castellani C;
J Cyst Fibros; 2007 Jan; 6(1):57-65. PubMed ID: 16870510
[TBL] [Abstract][Full Text] [Related]
35. Cost effectiveness of newborn screening for cystic fibrosis: a simulation study.
Nshimyumukiza L; Bois A; Daigneault P; Lands L; Laberge AM; Fournier D; Duplantie J; Giguère Y; Gekas J; Gagné C; Rousseau F; Reinharz D
J Cyst Fibros; 2014 May; 13(3):267-74. PubMed ID: 24238947
[TBL] [Abstract][Full Text] [Related]
36. Markedly elevated neonatal immunoreactive trypsinogen levels in the absence of cystic fibrosis gene mutations is not an indication for further testing.
Massie J; Curnow L; Tzanakos N; Francis I; Robertson CF
Arch Dis Child; 2006 Mar; 91(3):222-5. PubMed ID: 16243854
[TBL] [Abstract][Full Text] [Related]
37. Variation in immunoreactive trypsinogen concentrations among Michigan newborns and implications for cystic fibrosis newborn screening.
Korzeniewski SJ; Young WI; Hawkins HC; Cavanagh K; Nasr SZ; Langbo C; Teneyck KR; Grosse SD; Kleyn M; Grigorescu V
Pediatr Pulmonol; 2011 Feb; 46(2):125-30. PubMed ID: 20848586
[TBL] [Abstract][Full Text] [Related]
38. Novel strategies in newborn screening for cystic fibrosis: a prospective controlled study.
Vernooij-van Langen AM; Loeber JG; Elvers B; Triepels RH; Gille JJ; Van der Ploeg CP; Reijntjens S; Dompeling E; Dankert-Roelse JE;
Thorax; 2012 Apr; 67(4):289-95. PubMed ID: 22271776
[TBL] [Abstract][Full Text] [Related]
39. Secondhand Smoke Exposure and Serum Trypsinogen in Cystic Fibrosis Carriers.
Ellery KM; Kopp B; Conwell DL; Gariepy C
Pancreas; 2019 Oct; 48(9):1155-1159. PubMed ID: 31593019
[TBL] [Abstract][Full Text] [Related]
40. Retrospective analysis of stored dried blood spots from children with cystic fibrosis and matched controls to assess the performance of a proposed newborn screening protocol in Switzerland.
Barben J; Gallati S; Fingerhut R; Schoeni MH; Baumgartner MR; Torresani T;
J Cyst Fibros; 2012 Jul; 11(4):332-6. PubMed ID: 22300503
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]